论文部分内容阅读
数学模型预测结果显示,经对11～13岁的少女接种由葛兰素史克(GSK)的宫颈癌疫苗Cervarix有望降低子宫颈癌的发生率高达80%;该结果基于现有的临床数据得出。该预测模型分两个阶段构建。在第1阶段,接种子宫颈癌候选疫苗(该疫苗已显示出对抗HPV——人乳头状瘤病毒——两种主要的致癌病毒16型和18型的特效性,预计可使法国宫颈癌的发生率降低74%。在进一步的分析中,该模型加入初步证据(即除了HPV疫苗16型和18型所表现出的效用之外,葛兰素史克的子宫颈癌候选疫苗还显示出对癌症前期损害的明显保护);当模型增添这种额外的保护后,预计可使子宫颈癌的发病率再降低6%,从而使子宫颈癌的发生率共降低80%。这些发现目前已被递交给在丹麦哥本哈根举行的国际药物经济与产
Mathematical modeling predicts that Cervarix, a cervical cancer vaccine by GlaxoSmithKline (GSK), may reduce the incidence of cervical cancer by as much as 80% in adolescent girls aged 11 to 13 years; the results are based on available clinical data . The forecasting model is built in two phases. Vaccination of cervical cancer vaccine candidate Phase 1 (which has shown to be effective against HPV - human papillomavirus - the two major oncogenic viruses, type 16 and 18) is expected to cause cervical cancer in France In a further analysis, the model incorporates preliminary evidence that in addition to the efficacies shown by HPV vaccines types 16 and 18, GlaxoSmithKline’s cervical cancer vaccine candidate has shown promise for cancer Significant pre-injury protection); Additional additional protection of the model is expected to reduce the incidence of cervical cancer by another 6%, resulting in a total reduction of 80% in cervical cancer. These findings have now been submitted International pharmaceutical economy and production in Copenhagen, Denmark